Skip to main content

Table 5 Distribution of survey results and claims data in patient groups with and without prior discussion of the option of TJR by physician

From: Which disease-related factors influence patients’ and physicians’ willingness to consider joint replacement in hip and knee OA? Results of a questionnaire survey linked to claims data

  Symptomatic Hip OA Symptomatic Knee OA
Variable TJR discussed n = 215,
44% (weighted)
TJR not discussed n = 255,
56% (weighted)
TJR discussed n = 387,
45% (weighted)
TJR not discussed n = 524,
55% (weighted)
Age (years), mean 64 (62; 65) 65 (63; 66) 66 (65; 67) 64 (63; 65)
Female 61 (53; 68) 64 (57; 70) 64 (59; 68) 71 (68; 74)
BMI > 30 (kg/m2) 24 (17; 31) 26 (19; 33) 35 (29; 40) 39 (33; 44)
Symptom duration (years), mean 14 (12; 16) 14 (12; 16) 16 (14; 17) 13 (12; 15)
Deterioration of symptoms (during last 2 years) 64 (55; 73) 62 (54; 70) 67 (61; 72) 50 (44; 55)
WOMAC total, mean 43 (39; 46) 41 (38; 44) 46 (44; 49) 36 (34; 38)
WOMAC pain, mean 42 (38; 45) 43 (39; 46) 47 (45; 49) 37 (35; 40)
WOMAC function, mean 42 (38; 45) 40 (36; 43) 45 (42; 47) 35 (32; 37)
WOMAC stiffness, mean 44 (40; 49) 45 (42; 49) 50 (47; 53) 40 (38; 43)
Any impact on personal situation 89 (83; 94) 72 (64; 79) 85 (80; 89) 72 (67; 77)
WHO-5 51 (47; 56) 50 (46; 54) 48 (45; 51) 53 (50; 56)
Orthopaedist is treating 68 (60; 77) 58 (50; 67) 77 (72; 82) 68 (63; 73)
Opioid prescriptiona 14 (7; 20) 13 (8; 19) 17 (12; 21) 10 (7; 13)
Daily use of medication 24 (16; 32) 28 (20; 35) 27 (22; 33) 18 (14; 22)
Physical therapy prescriptiona 46 (37; 55) 45 (37; 54) 51 (45; 57) 47 (42; 52)
Patient desiring TJR: knee or hip 32 (24; 41) 5 (2; 8) 28 (22; 33) 3 (1; 5)
Having at least one artificial joint 36 (27; 45) 13 (7; 20) 29 (24; 34) 11 (7; 14)
  1. Values are percentages unless indicated otherwise. Values in brackets are 95% confidence intervals. a indicates information derived from claims data